After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of BridgeBio Pharma Inc is $14.26B. A total of 1.53 million shares were traded on the day, compared to an average of 2.30M shares.
In the most recent transaction, Kumar Neil sold 30,011 shares of BBIO for 74.64 per share on Dec 15 ’25. After the transaction, the Chief Executive Officer now owns 228,776 company shares. In a previous transaction on Dec 15 ’25, NEIL KUMAR bought 30,011 shares at 75.15 per share.
Among the insiders who sold shares, Apuli Maricel disposed of 2,000 shares on Dec 08 ’25 at a per-share price of $74.26. This resulted in the Chief Accounting Officer holding 130,297 shares of BBIO after the transaction. In another insider transaction, Kumar Neil sold 40,000 shares at $74.40 per share on Dec 04 ’25. Company shares held by the Chief Executive Officer now total 775,686.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, BBIO has a high of $76.51 and a low of $25.34.
As of this writing, BBIO has an earnings estimate of -$0.62 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of -$0.51 per share and a lower estimate of -$0.8. The company reported an EPS of -$1.37 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BBIO’s latest balance sheet shows that the firm has $836.66M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $135.07M in liabilities at the time. Its Book Value Per Share was -$10.03, while its Total Shareholder’s Equity was -$865.58M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.84.
